Altimmune (ALT) Cash from Operations (2010 - 2026)

Altimmune (ALT) has 17 years of Cash from Operations data on file, last reported at 20942000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 24.36% year-over-year to 20942000.0 in Q1 2026; TTM through Mar 2026 was 71637000.0, a 10.82% increase from a year earlier, with the FY2025 full-year figure at 67535000.0, up 15.42% from the prior year.
• Cash from Operations for Q1 2026 stood at 20942000.0, down from 19448000.0 in the prior quarter.
• Over the last five years, Cash from Operations for ALT reached as high as 11897000.0 in Q3 2025 and fell as low as 27118000.0 in Q3 2024.
• Historically, Cash from Operations has averaged 18042411.76 across 5 years, with a median of 18108000.0 in 2024.
• Across the five-year window, Cash from Operations plunged 43.48% in 2023 and jumped 56.13% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 17306000.0 in 2022, then grew by 4.47% to 16533000.0 in 2023, then dropped by 10.48% to 18265000.0 in 2024, then dropped by 6.48% to 19448000.0 in 2025, then decreased by 7.68% to 20942000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 20942000.0 in Q1 2026, 19448000.0 in Q4 2025, and 11897000.0 in Q3 2025.